Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

Despite novel therapeutic options, many people with type 2 diabetes (T2D) do not achieve their HbA1c targets. Given the progressive nature of T2D, many individuals not controlled with oral therapy will require advancement to injectable therapy using either a glucagon‐like peptide‐1 receptor agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez‐Peralta, Fernando, Al‐Ozairi, Ebaa, Jude, Edward B., Li, Xiaoying, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252507/
https://www.ncbi.nlm.nih.gov/pubmed/33651460
http://dx.doi.org/10.1111/dom.14365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252507/
https://www.ncbi.nlm.nih.gov/pubmed/33651460
http://dx.doi.org/10.1111/dom.14365

Ejemplares similares